Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement